Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited
Key Takeaways
- Contrave is not a GLP-1 medication; it is a combination of naltrexone and bupropion
- The two active ingredients work through opioid receptor antagonism and dopamine/norepinephrine reuptake inhibition, not through incretin biology
- Contrave is FDA-approved for chronic weight management but produces much smaller weight loss than GLP-1 RAs
- The drug works through central nervous system pathways, particularly hypothalamic POMC neurons and brain reward circuits
- Combining Contrave with a GLP-1 medication is sometimes done off-label by obesity specialists when single-drug therapy is insufficient
Direct answer
No, Contrave is not a GLP-1 medication. Contrave contains two active ingredients: naltrexone (an opioid receptor antagonist) and bupropion (a dopamine and norepinephrine reuptake inhibitor). Neither drug interacts with the GLP-1 receptor or any other incretin pathway. Contrave is FDA-approved for chronic weight management, but it sits in a completely separate drug class from semaglutide, tirzepatide, liraglutide, and the rest of the GLP-1 family.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The misconception, addressed directly
- What naltrexone is and what it does
- What bupropion is and what it does
- Why combining them works for weight loss
- The hypothalamus pathway in plain terms
- Clinical efficacy: what to expect on Contrave
- How Contrave compares to GLP-1 medications
- Side effects and the suicidality boxed warning
- Who Contrave is a good fit for
- The Contrave plus GLP-1 combination question
- Contrary view: is the GLP-1 framing crowding out other options?
- Decision framework
- FAQ
- Sources
The misconception, addressed directly
The question "is Contrave a GLP-1" comes up because Contrave appears in the same online conversations as Ozempic, Wegovy, and Mounjaro. All four are prescription medications. All four are FDA-approved for weight management. All four reduce appetite.
The mechanisms have nothing in common. GLP-1 RAs mimic a gut hormone called glucagon-like peptide-1, which signals through receptors in the pancreas, stomach, and brain. Contrave's two ingredients work on completely different brain pathways: opioid receptors and monoamine reuptake transporters.
The confusion is understandable. Both produce appetite suppression. Both are prescribed by obesity specialists, endocrinologists, and primary care doctors. Both require prior authorization with most insurance plans. But pharmacologically, calling Contrave a GLP-1 is like calling aspirin an antibiotic. They are both pills, both prescribed by doctors, both have effects, but the underlying biology is unrelated.
What naltrexone is and what it does
Naltrexone is an opioid receptor antagonist. It binds to mu, delta, and kappa opioid receptors and blocks them from being activated by opioids like morphine, heroin, or the body's own endogenous opioids (endorphins, enkephalins).
The drug has been used for decades in two primary settings:
- Opioid use disorder. Naltrexone blocks the rewarding effects of opioids, reducing relapse risk in patients in recovery. Both oral (ReVia) and long-acting injectable (Vivitrol) formulations are FDA-approved.
- Alcohol use disorder. Naltrexone reduces alcohol cravings and the rewarding effects of drinking by blocking endogenous opioid signaling that contributes to alcohol reward.
For weight management, naltrexone is used at much lower doses than in addiction medicine. The Contrave dose of 32 mg total daily (8 mg per tablet, four tablets daily at maintenance) is well below the typical 50 mg daily for alcohol use disorder.
Naltrexone alone produces only modest weight loss in clinical trials. The combination with bupropion produces synergy that single-drug therapy does not match.
What bupropion is and what it does
Bupropion is a monoamine reuptake inhibitor that primarily affects dopamine and norepinephrine. It blocks the reabsorption of these neurotransmitters at synapses, increasing their levels in brain regions involved in reward, motivation, and energy.
Bupropion has been used since the late 1980s for:
- Depression. Bupropion (Wellbutrin) is FDA-approved for major depressive disorder, with a different side-effect profile than SSRI antidepressants.
- Smoking cessation. Bupropion (Zyban) reduces nicotine cravings and withdrawal symptoms.
- Seasonal affective disorder. Bupropion XL prevents recurrence of seasonal depression in some patients.
The drug's effect on appetite is modest when used alone but well-documented. Many patients on bupropion for depression notice reduced appetite as a side effect. Some lose weight.
In Contrave, bupropion is dosed at 360 mg total daily (90 mg per tablet, four tablets daily at maintenance). This is similar to the bupropion dose used for depression.
Why combining them works for weight loss
The synergy between naltrexone and bupropion was discovered through research on hypothalamic appetite circuits. The relevant pathway involves a specific group of neurons in the arcuate nucleus called POMC neurons (pro-opiomelanocortin neurons).
POMC neurons release alpha-melanocyte-stimulating hormone (alpha-MSH), which suppresses appetite. The more these neurons fire, the less hungry you feel.
Two regulatory mechanisms modulate POMC neuron activity:
First, bupropion stimulates POMC neurons via dopamine and norepinephrine pathways. This increases firing and increases alpha-MSH release.
Second, when POMC neurons fire, they release beta-endorphin (an endogenous opioid) onto themselves in a negative feedback loop. The beta-endorphin binds to mu opioid receptors on the same neurons and slows their firing. This is a built-in brake on the appetite-suppressing signal.
Naltrexone blocks the mu opioid receptor, removing the brake. POMC neurons can fire more freely and for longer, sustaining the appetite-suppressing effect.
The combination produces a stronger and more sustained reduction in appetite than either drug alone. Clinical trials demonstrated the synergy, leading to the FDA approval of the combination as Contrave.
The hypothalamus pathway in plain terms
The arcuate nucleus of the hypothalamus is the brain's main appetite regulator. It contains two opposing populations of neurons:
- POMC neurons: suppress appetite (anorexigenic)
- AgRP/NPY neurons: stimulate appetite (orexigenic)
Body weight is regulated by the balance between these two systems. Leptin, insulin, GLP-1, ghrelin, and other hormones modulate the balance. Drugs that target the system can do so through either branch.
GLP-1 medications work primarily by activating receptors on POMC neurons and reducing activity in AgRP/NPY neurons. The effect is downstream of incretin signaling.
Contrave works directly on the POMC pathway via dopamine/norepinephrine stimulation (bupropion) and opioid disinhibition (naltrexone). It does not engage the incretin system.
Both classes ultimately produce reduced appetite, but through different upstream signals. This is why combining the two classes (Contrave plus a GLP-1) has been explored: the mechanisms are complementary rather than redundant.
Clinical efficacy: what to expect on Contrave
The COR (Contrave Obesity Research) trial program established the drug's efficacy:
COR-I (Greenway et al., Lancet 2010). Contrave vs placebo in adults with obesity. Mean weight loss at 56 weeks: 6.1 percent on Contrave vs 1.3 percent on placebo (per-protocol analysis). About 48 percent of Contrave patients lost at least 5 percent body weight, vs 16 percent on placebo.
COR-II. Contrave vs placebo with similar design. Mean weight loss at 56 weeks: about 6 to 8 percent on Contrave vs 1 to 2 percent placebo.
COR-BMOD. Contrave combined with intensive behavioral modification. Mean weight loss: 9.3 percent on Contrave vs 5.1 percent on placebo, both with behavioral support.
COR-Diabetes. Contrave in patients with obesity and type 2 diabetes. Mean weight loss: 5.0 percent on Contrave vs 1.8 percent on placebo, with modest A1C reduction.
Across the program, Contrave produced about 4 to 9 percent weight loss depending on the population and behavioral support. The intent-to-treat analysis (including patients who discontinued early) generally shows smaller effects than the per-protocol analysis.
How Contrave compares to GLP-1 medications
The efficacy gap between Contrave and GLP-1 medications is substantial:
| Medication | Mean weight loss | Dosing | Route |
|---|---|---|---|
| Contrave | 4-9% (varies by trial) | Twice daily, multiple pills | Oral |
| Saxenda (liraglutide) | ~5-8% | Daily | Injection |
| Wegovy (semaglutide) | ~14.9% (STEP 1) | Weekly | Injection |
| Zepbound (tirzepatide) | ~22.5% (SURMOUNT-1) | Weekly | Injection |
Patients who could tolerate either drug class would likely lose more weight on a GLP-1 medication or a dual agonist than on Contrave. The trade-offs:
- Contrave is oral; GLP-1s (except Rybelsus) are injections
- Contrave is generally cheaper than brand GLP-1s
- Contrave has different side effects (insomnia, dry mouth) and contraindications (seizure history)
- Contrave does not have cardiovascular outcome trial data; semaglutide (SELECT) does
For some patients, the oral route, lower cost, or specific side-effect profile makes Contrave preferable. For most patients seeking maximum weight loss, GLP-1 RAs or dual agonists outperform.
Side effects and the suicidality boxed warning
Contrave's side-effect profile reflects both component drugs:
- Nausea (about 33 percent of patients, often during titration)
- Constipation (about 19 percent)
- Headache (about 18 percent)
- Vomiting (about 11 percent)
- Dizziness (about 10 percent)
- Insomnia (about 9 percent)
- Dry mouth (about 8 percent)
- Diarrhea (about 7 percent)
The boxed warning addresses suicidal thoughts and behavior. Bupropion has a class-wide warning for antidepressants regarding increased suicidal ideation, particularly in patients under 24. Contrave inherits this warning. Patients should be monitored for mood changes, especially during initiation.
Other important warnings include:
- Seizure risk: bupropion is contraindicated in patients with seizure disorders, eating disorders, abrupt alcohol or benzodiazepine withdrawal, and other seizure risk factors
- Hypertension: Contrave can increase blood pressure and heart rate; monitor in patients with hypertension
- Hepatotoxicity: rare but reported; discontinue if liver injury occurs
- Allergic reactions: bupropion-related rash, urticaria, anaphylaxis
The drug should not be combined with opioid agonists. The naltrexone component blocks opioid effects, which can precipitate withdrawal in patients on opioids or block analgesia in patients who need opioid pain management.
Who Contrave is a good fit for
Despite smaller weight-loss effects than GLP-1 medications, Contrave fits well for certain patients:
- Patients who prefer oral medication over injection
- Patients with depression who could benefit from bupropion's antidepressant effect alongside weight management
- Patients with binge eating disorder, where the naltrexone-bupropion combination may reduce binge frequency
- Patients with co-occurring alcohol use disorder, where naltrexone has additional benefit
- Patients with cost or insurance barriers to GLP-1 medications
- Patients who cannot tolerate GLP-1 side effects (severe nausea, gallbladder issues, etc.)
Contrave is not appropriate for patients with seizure disorders, eating disorders (particularly anorexia or bulimia), chronic opioid use, uncontrolled hypertension, or significant cardiovascular disease.
The Contrave plus GLP-1 combination question
Because the two drug classes work through different mechanisms, combining them has theoretical appeal. Obesity specialists have explored Contrave plus GLP-1 RA combinations off-label for patients with inadequate weight loss on single-drug therapy.
The evidence base is still emerging. Small studies and case series suggest the combination can produce additional weight loss beyond either drug alone, with cumulative side effects (particularly nausea) being the main limiting factor. Drug-drug interactions are minimal, though both drugs can cause nausea, and adding them together amplifies the risk.
The COR-DIABETES trial and follow-up real-world studies provide some safety data on Contrave in patients on various background diabetes medications, but specific data on the Contrave plus GLP-1 RA combination is limited.
This combination is reasonable for patients under specialist care who have plateaued on single-drug therapy. It is not a first-line strategy and should be initiated cautiously with monitoring.
Contrary view: is the GLP-1 framing crowding out other options?
Most public conversation about prescription weight loss in 2026 focuses on GLP-1 medications. Contrave receives relatively little attention. Arguments that this imbalance is harmful:
First, Contrave is a real treatment option that fits certain patient profiles better than GLP-1 medications. Patients who cannot tolerate injections, cannot afford GLP-1s, or have contraindications to GLP-1s deserve to know about Contrave as an alternative.
Second, the obesity treatment landscape benefits from multiple classes. Different mechanisms work for different patients. A field dominated by one class loses diversity of options.
Third, combination therapy may produce better outcomes than maximizing single-drug therapy. The Contrave plus GLP-1 combination is one example. Patients who learn only about GLP-1 medications may not consider combination approaches.
Fourth, the social and cultural focus on GLP-1 medications creates a kind of monoculture in patient expectations. Patients who do not achieve dramatic weight loss on a GLP-1 may give up rather than try other options.
The counterargument: GLP-1 medications and dual agonists genuinely produce more weight loss than Contrave or other alternatives. Public attention reflects clinical reality, not market distortion. Patients should know about the most effective options first.
The reasonable position: Contrave is a smaller-effect drug with a distinct mechanism that serves specific patient populations well. The current emphasis on GLP-1 medications is justified by their efficacy, but Contrave deserves more visibility than it receives in patient-facing content.
Decision framework
If you are asking whether Contrave is a GLP-1:
- No. Contrave is naltrexone-bupropion, a completely different mechanism from GLP-1 RAs.
- Both are FDA-approved for chronic weight management, but the drug classes are unrelated.
If you are choosing between Contrave and a GLP-1:
- GLP-1 medications produce more weight loss on average.
- Contrave is oral; most GLP-1s are injections.
- Contrave fits patients with depression, binge eating, alcohol use disorder, or specific GLP-1 contraindications.
If you are currently on Contrave:
- The drug is producing real effects through bupropion and naltrexone mechanisms.
- If results are inadequate, ask whether adding a GLP-1 or switching is appropriate.
- Do not combine Contrave with opioid pain medications.
If you have specific contraindications:
- Seizure disorder: Contrave is contraindicated.
- Active opioid use: Contrave is contraindicated.
- Eating disorder (anorexia, bulimia): Contrave is contraindicated.
- Uncontrolled hypertension: caution; monitor blood pressure carefully.
FAQ
Is Contrave a GLP-1? No. Contrave is a combination of naltrexone and bupropion. Neither component acts on the GLP-1 receptor.
What is Contrave? An oral combination tablet with 8 mg naltrexone and 90 mg bupropion. FDA-approved for chronic weight management.
How does Contrave work? Bupropion stimulates POMC neurons in the hypothalamus; naltrexone removes opioid feedback inhibition. The combined effect reduces appetite.
Why do people think Contrave is a GLP-1? Both are prescription weight-loss medications that reduce appetite. The mechanisms differ entirely.
How much weight do people lose on Contrave? About 4 to 9 percent of body weight in trials, depending on the study and analysis method. Less than GLP-1 medications.
What are the side effects of Contrave? Common: nausea, constipation, headache, vomiting, dizziness, insomnia. Serious: suicidal thoughts (boxed warning), seizures (bupropion-related), hypertension.
When was Contrave FDA-approved? September 10, 2014.
Can I take Contrave with a GLP-1? Off-label combinations are used by some specialists when single-drug therapy is insufficient. Discuss with a clinician.
Is Contrave safe? When prescribed appropriately and screened for contraindications, Contrave has an acceptable safety profile. The boxed warning for suicidal thoughts requires monitoring.
Can Contrave help with binge eating? The combination of naltrexone and bupropion may reduce binge frequency in some patients. Naltrexone has off-label evidence for binge eating disorder.
Why is Contrave cheaper than Wegovy? The active ingredients (naltrexone, bupropion) are generic and inexpensive. The combination formulation is branded, but the underlying drugs have been off patent for years.
Who should not take Contrave? Patients with seizure disorders, eating disorders, chronic opioid use, uncontrolled hypertension, abrupt alcohol or benzodiazepine withdrawal, and other contraindications listed in prescribing information.
Sources
- FDA Prescribing Information. Contrave (naltrexone/bupropion). Updated 2024.
- Greenway FL et al. Effect of Naltrexone Plus Bupropion on Weight Loss in Overweight and Obese Adults (COR-I). Lancet. 2010.
- Apovian CM et al. A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-Related Risk Factors (COR-II). Obesity. 2013.
- Wadden TA et al. Weight Loss with Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification (COR-BMOD). Obesity. 2011.
- Hollander P et al. Effects of Naltrexone Sustained-Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients with Type 2 Diabetes (COR-Diabetes). Diabetes Care. 2013.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
- Billes SK et al. Naltrexone/Bupropion for Obesity: An Investigational Combination Pharmacotherapy for Weight Loss. Pharmacological Research. 2014.
- Garvey WT et al. AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
- Obesity Society. Pharmacotherapy for Obesity Position Statement. 2024.
- American Diabetes Association. Standards of Medical Care in Diabetes. 2025.
Footer disclaimers
Platform Disclaimer. FormBlends is a telehealth platform connecting users with independent licensed clinicians and U.S. pharmacies. We do not own a pharmacy, employ providers, or provide medical care directly. Treatment decisions are made by the prescribing clinician based on individual evaluation.
Compounded Medication Notice. Compounded GLP-1 preparations (semaglutide, tirzepatide) provided through telehealth platforms are not FDA-approved. State-licensed 503A pharmacies prepare these in response to individual prescriptions. They are not equivalent to FDA-approved brand products like Wegovy, Zepbound, Ozempic, or Mounjaro. Contrave is an FDA-approved combination product; it is not typically compounded.
Results Disclaimer. Clinical trial averages reflect controlled study populations. Real-world outcomes vary based on dose tolerance, adherence, dietary patterns, exercise habits, baseline weight, and biological factors. Comparing weight-loss medications based on average trial outcomes does not predict any specific patient's response.
Trademark Notice. Contrave is a registered trademark of Currax Pharmaceuticals (and historically Orexigen Therapeutics and Nalpropion Pharmaceuticals). Wellbutrin, Zyban, and Aplenzin are registered trademarks of bupropion-marketing companies. ReVia and Vivitrol are registered trademarks of naltrexone-marketing companies. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends has no affiliation with any of these manufacturers.